July 19, 2021 04:51 AM EDTUpdated 05:56 AM
Financing
Bioregnum

Till­man Gern­gross is bet­ting well over $500M that the pan­dem­ic will nev­er re­al­ly end. Here’s the IPO pitch

Till­man Gern­gross doesn’t waf­fle.

The long­time Dart­mouth pro­fes­sor and Adimab founder tends to pick a course and dri­ve straight for the goal. If he sees …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times